Immune Checkpoint Inhibition in Breast Cancer

Publication
Article
Special ReportsBreast Cancer (Issue 1)
Volume 1
Issue 1

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, comments on immune checkpoint inhibition for the treatment of breast cancer.

<<<

Back to the Breast Cancer Special Report

Related Videos
Video 5 - "Second-Line Treatment Considerations and Improving Outcomes in Breast Cancer"
Video 4 - "Impressions on Safety Data from EMERALD Subgroup Analysis"
Video 3 - "EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer"
Video 2 - "Importance of Biomarker Testing in Breast Cancer"
Video 1 - "Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases"
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Related Content